Future Perspectives and Unmet Needs in CLL

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Developers are expected to file a supplemental NDA for revumenib in NPM1-mutated AML in the first half of 2025.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.